Referencia número: HY-16563

Narciclasine

Name: Narciclasine
Brand: MedChemExpress
SKU: HY-16563
Price: 128.00 USD
Availability: InStock
Rating: 5 (23 reviews)

(Synonyms: Lycoricidinol)

23 Cited Publications

Revisión del cliente

Based on 23 publication(s) in Google Scholar

Narciclasine is a plant growth modulator. Narciclasine modulates the Rho/Rho kinase/LIM kinase/cofilin signaling pathway, greatly increasing GTPase RhoA activity as well as inducing actin stress fiber formation in a RhoA-dependent manner.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza: 99.67%
No. CAS: 29477-83-6
Fòrmula: C₁₄H₁₃NO₇
Peso molecular:307.26

Almacenamiento:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Narciclasine Chemical Structure

No. CAS: 29477-83-6

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (23)
Solvente y solubilidad
- In Vitro
- In Vivo
Protocolo
Pureza y Documentación
Referencias
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

IC₅₀ & Target^[1]

ROCK

Ver todos los productos específicos de isoformas ROCK :

Cellular Effect

Cell Line	Type	Value	Description	References
9L	IC₅₀	32 nM Compound: 1	Antiproliferative activity against rat 9L cells Antiproliferative activity against rat 9L cells	[PMID: 19199649]
A549	IC₅₀	0.03 μM Compound: 1	Cytotoxicity against human A549 cells after 3 days by MTT assay Cytotoxicity against human A549 cells after 3 days by MTT assay	[PMID: 19199649]
A549	IC₅₀	0.05 μM Compound: narciclasine	Growth inhibition of apoptosis-resistant human A549 cells after 72 hrs by MTT assay Growth inhibition of apoptosis-resistant human A549 cells after 72 hrs by MTT assay	[PMID: 20415482]
A549	IC₅₀	29 nM Compound: 1	Antiproliferative activity against human A549 cells by MTT assay Antiproliferative activity against human A549 cells by MTT assay	[PMID: 19199649]
B16-F10	IC₅₀	0.05 μM Compound: narciclasine	Growth inhibition of apoptosis-sensitive mouse B16F10 cells after 72 hrs by MTT assay Growth inhibition of apoptosis-sensitive mouse B16F10 cells after 72 hrs by MTT assay	[PMID: 20415482]
B16-F10	IC₅₀	35 nM Compound: 1	Antiproliferative activity against mouse B16F10 cells Antiproliferative activity against mouse B16F10 cells	[PMID: 19199649]
BXPC-3	ED₅₀	0.0035 μg/mL Compound: 2a	Growth inhibition of human BXPC3 cells after 48 hrs Growth inhibition of human BXPC3 cells after 48 hrs	[PMID: 17346078]
BXPC-3	ED₅₀	0.024 μg/mL Compound: 2	Cytotoxicity against human BxPC3 cells after 48 hrs by SRB assay Cytotoxicity against human BxPC3 cells after 48 hrs by SRB assay	[PMID: 16124772]
BXPC-3	GI₅₀	0.0035 μg/mL Compound: 2a	Cytotoxicity against human BxPC3 cells Cytotoxicity against human BxPC3 cells	[PMID: 15043403]
BXPC-3	IC₅₀	0.03 μM Compound: 1	Cytotoxicity against human BxPC3 cells after 3 days by MTT assay Cytotoxicity against human BxPC3 cells after 3 days by MTT assay	[PMID: 19199649]
BXPC-3	IC₅₀	0.05 μM Compound: 2a	Antiproliferative activity against human BxPC3 cells assessed as viable cells after 48 hrs by MTT assay Antiproliferative activity against human BxPC3 cells assessed as viable cells after 48 hrs by MTT assay	[PMID: 21757350]
BXPC-3	IC₅₀	0.05 μM Compound: 3	Cytotoxicity against human BxPC3 cells Cytotoxicity against human BxPC3 cells	[PMID: 25108300]
BXPC-3	IC₅₀	28 nM Compound: 1	Antiproliferative activity against human BxPC3 cells by MTT assay Antiproliferative activity against human BxPC3 cells by MTT assay	[PMID: 19199649]
C32	IC₅₀	25 nM Compound: 1	Antiproliferative activity against human C32 cells by MTT assay Antiproliferative activity against human C32 cells by MTT assay	[PMID: 19199649]
C6	IC₅₀	28 nM Compound: 1	Antiproliferative activity against rat C6 cells Antiproliferative activity against rat C6 cells	[PMID: 19199649]
Daoy	IC₅₀	22 nM Compound: 1	Antiproliferative activity against human DaOY cells by MTT assay Antiproliferative activity against human DaOY cells by MTT assay	[PMID: 19199649]
Detroit 562	IC₅₀	6 nM Compound: 1	Antiproliferative activity against human Detroit 562 cells by MTT assay Antiproliferative activity against human Detroit 562 cells by MTT assay	[PMID: 19199649]
DU-145	ED₅₀	0.012 μg/mL Compound: 2	Cytotoxicity against human DU145 cells after 48 hrs by SRB assay Cytotoxicity against human DU145 cells after 48 hrs by SRB assay	[PMID: 16124772]
DU-145	GI₅₀	0.0032 μg/mL Compound: 2a	Growth inhibition of human DU145 cells after 48 hrs Growth inhibition of human DU145 cells after 48 hrs	[PMID: 17346078]
DU-145	GI₅₀	0.0032 μg/mL Compound: 2a	Cytotoxicity against human DU145 cells Cytotoxicity against human DU145 cells	[PMID: 15043403]
DU-145	GI₅₀	0.011 μg/mL Compound: 2a	Growth inhibition of human DU145 cells Growth inhibition of human DU145 cells	[PMID: 16441059]
DU-145	IC₅₀	0.03 μM Compound: 3	Cytotoxicity against human DU145 cells Cytotoxicity against human DU145 cells	[PMID: 25108300]
DU-145	IC₅₀	0.05 μM Compound: 2a	Antiproliferative activity against human DU145 cells assessed as viable cells after 48 hrs by MTT assay Antiproliferative activity against human DU145 cells assessed as viable cells after 48 hrs by MTT assay	[PMID: 21757350]
FaDu	IC₅₀	8 nM Compound: 1	Antiproliferative activity against human FADU cells by MTT assay Antiproliferative activity against human FADU cells by MTT assay	[PMID: 19199649]
G-361	IC₅₀	99 nM Compound: 1	Antiproliferative activity against human G361 cells by MTT assay Antiproliferative activity against human G361 cells by MTT assay	[PMID: 19199649]
HCT-15	IC₅₀	32 nM Compound: 1	Antiproliferative activity against human HCT15 by MTT assay Antiproliferative activity against human HCT15 by MTT assay	[PMID: 19199649]
Hs 683	GI₅₀	0.04 μM Compound: Narciclasine	Growth inhibition of human Hs683 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Growth inhibition of human Hs683 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 27157005]
Hs 683	IC₅₀	0.05 μM Compound: narciclasine	Growth inhibition of apoptosis-sensitive human Hs 683 cells after 72 hrs by MTT assay Growth inhibition of apoptosis-sensitive human Hs 683 cells after 72 hrs by MTT assay	[PMID: 20415482]
Hs 683	IC₅₀	40 nM Compound: 1	Antiproliferative activity against human Hs 683 cells by MTT assay Antiproliferative activity against human Hs 683 cells by MTT assay	[PMID: 19199649]
HT-144	IC₅₀	38 nM Compound: 1	Antiproliferative activity against human HT144 cells by MTT assay Antiproliferative activity against human HT144 cells by MTT assay	[PMID: 19199649]
HUVEC	IC₅₀	87 nM Compound: 1	Antiproliferative activity against human HUVEC (HTG04) cells Antiproliferative activity against human HUVEC (HTG04) cells	[PMID: 19199649]
HUVEC	IC₅₀	94 nM Compound: 1	Antiproliferative activity against human HUVEC (HTG07) cells Antiproliferative activity against human HUVEC (HTG07) cells	[PMID: 19199649]
HUVEC	IC₅₀	97 nM Compound: 1	Antiproliferative activity against human HUVEC (HTG06) cells Antiproliferative activity against human HUVEC (HTG06) cells	[PMID: 19199649]
KM-20L2	ED₅₀	0.023 μg/mL Compound: 2	Cytotoxicity against human KM20L2 cells after 48 hrs by SRB assay Cytotoxicity against human KM20L2 cells after 48 hrs by SRB assay	[PMID: 16124772]
KM-20L2	GI₅₀	0.0032 μg/mL Compound: 2a	Growth inhibition of human KM20L2 cells after 48 hrs Growth inhibition of human KM20L2 cells after 48 hrs	[PMID: 17346078]
KM-20L2	GI₅₀	0.0032 μg/mL Compound: 2a	Cytotoxicity against human KM20L2 cells Cytotoxicity against human KM20L2 cells	[PMID: 15043403]
KM-20L2	GI₅₀	0.21 μg/mL Compound: 2a	Growth inhibition of human KM20L2 cells Growth inhibition of human KM20L2 cells	[PMID: 16441059]
LoVo	IC₅₀	0.09 μM Compound: 1	Cytotoxicity against human LoVo cells after 3 days by MTT assay Cytotoxicity against human LoVo cells after 3 days by MTT assay	[PMID: 19199649]
LoVo	IC₅₀	94 nM Compound: 1	Antiproliferative activity against human LoVo cells by MTT assay Antiproliferative activity against human LoVo cells by MTT assay	[PMID: 19199649]
MCF7	ED₅₀	0.0032 μg/mL Compound: 2a	Growth inhibition of human MCF7 cells after 48 hrs Growth inhibition of human MCF7 cells after 48 hrs	[PMID: 17346078]
MCF7	ED₅₀	0.014 μg/mL Compound: 2	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 16124772]
MCF7	GI₅₀	0.0032 μg/mL Compound: 2a	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 15043403]
MCF7	GI₅₀	0.019 μg/mL Compound: 2a	Growth inhibition of human MCF7 cells Growth inhibition of human MCF7 cells	[PMID: 16441059]
MCF7	IC₅₀	0.01 μM Compound: 4	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 22921081]
MCF7	IC₅₀	0.04 μM Compound: 2a	Antiproliferative activity against human MCF7 cells assessed as viable cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as viable cells after 48 hrs by MTT assay	[PMID: 21757350]
MCF7	IC₅₀	0.05 μM Compound: 1	Cytotoxicity against human MCF7 cells after 3 days by MTT assay Cytotoxicity against human MCF7 cells after 3 days by MTT assay	[PMID: 19199649]
MCF7	IC₅₀	45 nM Compound: 1	Antiproliferative activity against human MCF7 cells by MTT assay Antiproliferative activity against human MCF7 cells by MTT assay	[PMID: 19199649]
MDA-MB-231	IC₅₀	5 nM Compound: 1	Antiproliferative activity against human MDA-MB-231 cells by MTT assay Antiproliferative activity against human MDA-MB-231 cells by MTT assay	[PMID: 19199649]
NCI-H460	ED₅₀	0.014 μg/mL Compound: 2	Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay	[PMID: 16124772]
NCI-H460	GI₅₀	0.0084 μg/mL Compound: 2a	Growth inhibition of human NCI-H460 cells after 48 hrs Growth inhibition of human NCI-H460 cells after 48 hrs	[PMID: 17346078]
NCI-H460	GI₅₀	0.0084 μg/mL Compound: 2a	Cytotoxicity against human NCI-H460 cells Cytotoxicity against human NCI-H460 cells	[PMID: 15043403]
NCI-H460	GI₅₀	0.032 μg/mL Compound: 2a	Growth inhibition of human NCI-H460 cells Growth inhibition of human NCI-H460 cells	[PMID: 16441059]
NCI-H460	IC₅₀	0.04 μM Compound: 2a	Antiproliferative activity against human NCI-H460 cells assessed as viable cells after 48 hrs by MTT assay Antiproliferative activity against human NCI-H460 cells assessed as viable cells after 48 hrs by MTT assay	[PMID: 21757350]
NCI-H460	IC₅₀	0.05 μM Compound: 3	Cytotoxicity against human NCI-H460 cells Cytotoxicity against human NCI-H460 cells	[PMID: 25108300]
P388	ED₅₀	0.0012 μg/mL Compound: 2a	Growth inhibition of murine P388 cells after 48 hrs Growth inhibition of murine P388 cells after 48 hrs	[PMID: 17346078]
P388	ED₅₀	0.002 μg/mL Compound: 2a	Growth inhibition of mouse P388 cells Growth inhibition of mouse P388 cells	[PMID: 16441059]
P388	ED₅₀	0.013 μg/mL Compound: 2a	Cytotoxicity against mouse P388 cells Cytotoxicity against mouse P388 cells	[PMID: 15043403]
P388	ED₅₀	0.018 μg/mL Compound: 2	Cytotoxicity against mouse P388 cells after 48 hrs by cell counting Cytotoxicity against mouse P388 cells after 48 hrs by cell counting	[PMID: 22413911]
P388	ED₅₀	0.018 μg/mL Compound: 2	Cytotoxicity against mouse P388 cells Cytotoxicity against mouse P388 cells	[PMID: 16124772]
Panel NCI-60 (60 carcinoma cell lines)	GI₅₀	45 nM Compound: Narciclasine	Growth inhibitory activity against human cancer cell line in the NCI's anticancer drug screening program Growth inhibitory activity against human cancer cell line in the NCI's anticancer drug screening program	[PMID: 15743190]
PC-3	IC₅₀	0.03 μM Compound: 1	Cytotoxicity against human PC3 cells after 3 days by MTT assay Cytotoxicity against human PC3 cells after 3 days by MTT assay	[PMID: 19199649]
PC-3	IC₅₀	28 nM Compound: 1	Antiproliferative activity against human PC3 cells by MTT assay Antiproliferative activity against human PC3 cells by MTT assay	[PMID: 19199649]
RPMI-2650	IC₅₀	14 nM Compound: 1	Antiproliferative activity against human RPMI 2650 cells by MTT assay Antiproliferative activity against human RPMI 2650 cells by MTT assay	[PMID: 19199649]
SF-268	ED₅₀	0.018 μg/mL Compound: 2	Cytotoxicity against human SF268 cells after 48 hrs by SRB assay Cytotoxicity against human SF268 cells after 48 hrs by SRB assay	[PMID: 16124772]
SF-268	GI₅₀	0.0031 μg/mL Compound: 2a	Growth inhibition of human SF268 cells after 48 hrs Growth inhibition of human SF268 cells after 48 hrs	[PMID: 17346078]
SF-268	GI₅₀	0.0031 μg/mL Compound: 2a	Cytotoxicity against human SF268 cells Cytotoxicity against human SF268 cells	[PMID: 15043403]
SK-MEL-28	IC₅₀	0.05 μM Compound: narciclasine	Growth inhibition of apoptosis-resistant human SK-MEL-28 cells after 72 hrs by MTT assay Growth inhibition of apoptosis-resistant human SK-MEL-28 cells after 72 hrs by MTT assay	[PMID: 20415482]
SK-MEL-28	IC₅₀	37 nM Compound: 1	Antiproliferative activity against human SK-MEL-28 cells by MTT assay Antiproliferative activity against human SK-MEL-28 cells by MTT assay	[PMID: 19199649]
T98G	IC₅₀	48 nM Compound: 1	Antiproliferative activity against human T98G cells by MTT assay Antiproliferative activity against human T98G cells by MTT assay	[PMID: 19199649]
U-373MG ATCC	GI₅₀	0.029 μM Compound: Narciclasine	Growth inhibition of human U373 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Growth inhibition of human U373 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 27157005]
U-373MG ATCC	IC₅₀	0.03 μM Compound: 1	Cytotoxicity against human U373 cells after 3 days by MTT assay Cytotoxicity against human U373 cells after 3 days by MTT assay	[PMID: 19199649]
U-373MG ATCC	IC₅₀	0.05 μM Compound: narciclasine	Growth inhibition of apoptosis-resistant human U373 cells after 72 hrs by MTT assay Growth inhibition of apoptosis-resistant human U373 cells after 72 hrs by MTT assay	[PMID: 20415482]
U-373MG ATCC	IC₅₀	29 nM Compound: 1	Antiproliferative activity against human U373 cells by MTT assay Antiproliferative activity against human U373 cells by MTT assay	[PMID: 19199649]
U-87MG ATCC	IC₅₀	98 nM Compound: 1	Antiproliferative activity against human U87 cells by MTT assay Antiproliferative activity against human U87 cells by MTT assay	[PMID: 19199649]
Vero	IC₅₀	0.006 μg/mL Compound: 1	Antiviral activity against Yellow fever virus Ashibi infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against Yellow fever virus Ashibi infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 1336040]
Vero	IC₅₀	0.0074 μg/mL Compound: 1	Antiviral activity against Punta Toro virus Adames infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against Punta Toro virus Adames infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 1336040]
Vero	IC₅₀	0.008 μg/mL Compound: 1	Antiviral activity against Japanese encephalitis virus Nakayama infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against Japanese encephalitis virus Nakayama infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 1336040]
Vero	IC₅₀	0.015 μg/mL Compound: 1	Antiviral activity against Dengue virus type 4 infected in african green monkey Vero cells after 6 days by plaque reduction assay Antiviral activity against Dengue virus type 4 infected in african green monkey Vero cells after 6 days by plaque reduction assay	[PMID: 1336040]
WI-38	IC₅₀	317 nM Compound: 1	Antiproliferative activity against human WI38 cells Antiproliferative activity against human WI38 cells	[PMID: 19199649]

In Vitro

Narciclasine activates Rho and stress fibers in glioblastoma multiforme cells. The mean IC₅₀ of ~50 nM calculated on the 6 human glioblastoma multiforme (U373, Hs683, GL19, GL5, GL16, GL17), The mean IC₅₀ value of 47 nM for Narciclasine across a panel of 60 cancer cell lines^[1]. Bioassay-guided fractionation of the A. belladonna extract resulted in the identification of lycorine as the bio-active compound. The IC₅₀ measured for radicle growth inhibition is 0.1 μM for Narciclasine^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

The i.v. regimen of Narciclasine at 1 mg/kg significantly (P=0.02) increases the survival of GL19 glioblastoma multiforme-bearing mice. Narciclasine when given orally at the same dose five times a week for 5 consecutive weeks also significantly increases animal survival in this model (P=0.008). Oral treatment with Narciclasine at 1 mg/kg significantly increases the survival (P=0.004) of Hs683 glioblastoma multiforme-bearing mice. Increasing the number of doses administered per week does not increase the survival of these Hs683 glioblastoma multiforme-bearing mice. Narciclasine appears to show similar increased survival in these models to temozolomide but at appreciable lower doses and following both oral and i.v. administration^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

No. CAS 29477-83-6
Appearance Solid
Peso molecular 307.26
Fòrmula C₁₄H₁₃NO₇
Color White to yellow
SMILES

O=C1N[C@@]2([H])[C@H](O)[C@H](O)[C@@H](O)C=C2C3=C1C(O)=C4C(OCO4)=C3
Synonyms

Lycoricidinol
Structure Classification
- Alkaloids
- Isoquinoline Alkaloids
Initial Source
Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (23)

All Cell Proliferation/Viability AssayWBCell Imaging/StainingELISAIn Vivo Efficacy Study

Sort by:

Journal Impact Factor

Research (Wash D C)

The Mechanics of Tumor Cells Dictate Malignancy via Cytoskeleton-Mediated APC/Wnt/β-Catenin Signaling. [Abstract]

2023 Sep 21:6:0224. PMID: 37746658
Cell Mol Biol Lett

Narciclasine enhances cisplatin-induced apoptotic cell death by inducing unfolded protein response-mediated regulation of NOXA and MCL1. [Abstract]

2025 May 14;30(1):59. PMID: 40369444

Narciclasine purchased from MedChemExpress. Usage Cited in: Cell Mol Biol Lett. 2025 May 14;30(1):59. [Abstract]

A549 tumor spheroids were treated with various concentrations of Cisplatin or Narciclasine (0.001, 0.01, 0.1, 1, 10, 100 μM) for 72 h, and cell viability was determined by measuring cellular adenosine triphosphate (ATP) content.

Narciclasine purchased from MedChemExpress. Usage Cited in: Cell Mol Biol Lett. 2025 May 14;30(1):59. [Abstract]

Whole-cell lysates were prepared from A549 tumor spheroids 48 h after treatment with Cisplatin, Narciclasine (0.3 μM), or the combination. The levels of cleaved caspases were analyzed by western blotting.

Narciclasine purchased from MedChemExpress. Usage Cited in: Cell Mol Biol Lett. 2025 May 14;30(1):59. [Abstract]

Tumor spheroids were treated with Cisplatin, Narciclasine (0.3 μM), or the combination for 48 h. Live cells were stained green with calcein-acetoxymethyl ester, whereas dead cells were stained red with ethidium homodimer-1.

Narciclasine purchased from MedChemExpress. Usage Cited in: Cell Mol Biol Lett. 2025 May 14;30(1):59. [Abstract]

A549 tumor spheroids were treated with Cisplatin, Narciclasine (0.3 μM), or the combination for 48 h, and apoptosis was analyzed using a Cell Death Detection ELISA kit capable of detecting mono-and oligonucleosomes.

Narciclasine purchased from MedChemExpress. Usage Cited in: Cell Mol Biol Lett. 2025 May 14;30(1):59. [Abstract]

The weight of the excised tumors was measured 25 days after Cisplatin, Narciclasine (1 mg/kg, i.p.), or the combination.
Acta Biomater

Nanoparticle-mediated specific elimination of soft cancer stem cells by targeting low cell stiffness. [Abstract]

2021 Nov:135:493-505. PMID: 34492369
J Orthop Translat

MAGI1 attenuates osteoarthritis by regulating osteoclast fusion in subchondral bone through the RhoA-ROCK1 signaling pathway. [Abstract]

2025 Apr 23:52:167-181. PMID: 40322041
Int J Biol Macromol

Cumulus cells orchestrate oocyte maturation via actin polymerization and vitamin B6 metabolism regulation: Highlights from multi-omics analysis in sheep vitrified cumulus-oocyte complex. [Abstract]

2025 Jul 21;320(Pt 4):146219. PMID: 40701463
Clin Transl Med

Uterus globulin associated protein 1 (UGRP1) binds podoplanin (PDPN) to promote a novel inflammation pathway during Streptococcus pneumoniae infection. [Abstract]

2022 Jun;12(6):e850. PMID: 35652821
Life Sci

Sema3A - mediated modulation of NR1D1 expression may be involved in the regulation of axonal guidance signaling by the microbiota. [Abstract]

2019 Apr 15:223:54-61. PMID: 30872177
Bioeng Transl Med

Unique osteogenic profile of bone marrow stem cells stimulated in perfusion bioreactor is Rho-ROCK-mediated contractility dependent. [Abstract]

2023 Mar 17;8(3):e10509. PMID: 37206242
Pharmaceuticals (Basel)

9-Methylfascaplysin, a Marine-Derived Bioactive Compound, Promotes Neurite Outgrowth via the Inhibition of ROCK2. [Abstract]

2025 Nov 17;18(11):1751. PMID: 41304993
Int J Mol Sci

Narciclasine as a Novel Treatment for Lung Cancer and Malignant Pleural Mesothelioma: Insights from 3D Tumor Spheroid Models. [Abstract]

2025 Oct 17;26(20):10127. PMID: 41155419
Inflammation

Narciclasine Alleviates Endothelial Inflammation and Atherosclerosis Initiation by Inhibiting Histone Lactylation-Mediated NF-κB Activation. [Abstract]

2026 Jan 16;49(1):49. PMID: 41543766
iScience

Perturbational Gene-Expression Signatures for Combinatorial Drug Discovery. [Abstract]

2019 May 31:15:291-306. PMID: 31102995
Funct Integr Genomics

Narciclasine attenuates sepsis-associated acute kidney injury through the ESR1/S100A11 axis. [Abstract]

2025 Jan 14;25(1):13. PMID: 39808340
Cell Immunol

Narciclasine ameliorated T cell mediated acute liver injury through activating AMPK pathway. [Abstract]

2022 Dec:382:104631. PMID: 36272268
Biomed Res Int

Gentiopicroside Produces Endothelium-Independent Vasodilation by Deactivating the PI3K/Akt/Rho-Kinase Pathway in Isolated Rat Thoracic Aorta. [Abstract]

2021 May 14:2021:5565748. PMID: 34095301
Vet Microbiol

Narciclasine restricts pseudorabies virus replication in vitro and in vivo and has potential broad-spectrum antiviral activity. [Abstract]

2026 Jun:317:111034. PMID: 42019319
Virology

The actin cytoskeleton is important for pseudorabies virus infection. [Abstract]

2024 Dec:600:110233. PMID: 39255726
Exp Ther Med

Cadmium exposure enhances VE-cadherin expression in endothelial cells via suppression of ROCK signaling. [Abstract]

2022 May;23(5):355. PMID: 35481222
bioRxiv

2026 Mar 18.
Res Sq

2026 Mar 11.
SSRN

2025 Sep 4.
Hong Kong Polytechnic University

2021 Nov.
Heliyon

Enhancement of the IFN-β-induced host signature informs repurposed drugs for COVID-19. [Abstract]

2020 Dec;6(12):e05646. PMID: 33289002

Solvente y solubilidad

In Vitro:

DMSO : 200 mg/mL (650.91 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.2546 mL

16.2729 mL

32.5457 mL

5 mM

0.6509 mL

3.2546 mL

6.5091 mL

10 mM

0.3255 mL

1.6273 mL

3.2546 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1.67 mg/mL (5.44 mM); Clear solution

This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 1.67 mg/mL (5.44 mM); Clear solution

This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 1.67 mg/mL (5.44 mM); Clear solution

This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocolo

Kinase Assay^[1]

The RhoA G-LISA assay is used. The assay uses a 96-well plate coated with the Rho binding domain of Rho family effector proteins. The active GTP-bound form of the Rho family protein but not the inactive GDP-bound form from biological samples will bind to the plate. Bound active Rho family protein is then detected by incubation with a specific primary antibody followed by a secondary antibody conjugated to horseradish peroxidase. The signal is then developed using OPD. U373 and GL19 glioblastoma multiforme cells are serum starved for 24 h and left untreated or treated with Narciclasine (100 nM) for 3 min, 5 min, 30 min, 1 h, and 2 h or treated with 2.0 μg/mL of the cell-permeable Rho inhibitor for 4 h in serum-free medium at 37°C with and without subsequent Narciclasine treatment. This product consists of highly purified C3 transferase covalently linked to a proprietary cell-penetrating moiety via a disulfide bond. The cell-penetrating moiety allows rapid and efficient transport through the plasma membrane. Once in the cytosol, the cell-penetrating moiety is released, thereby allowing C3 transferase to freely diffuse intracellularly and inactive RhoA, RhoB, and RhoC but not related GTPases such as Cdc42 or Rac1. C3 transferase inhibits Rho proteins by ADP ribosylation on Asn⁴¹ in the effector binding domain of the GTPase. Cells are then lysed and RhoA activity is measured by the RhoA G-LISA Activation Assay or alternatively cells are stained for F-actin^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay

Cell^[1]The Narciclasine IC₅₀ concentration, the Narciclasine concentration that decreased by 50% the global growth rate of a given cell population, is assessed with the MTT assay. The cells are incubated for 72 h in the presence and absence of the Narciclasine (with concentrations ranging between 10^-9 and 10^-5 M concentrate) for the determination of Narciclasine IC₅₀ values^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]

Mice^[1]
The Hs683 cell line and GL19 primoculture grafted into the brains of nude immunodeficient mice both produced invasive brain tumors. Xenograft-bearing mice receive vehicle alone, oral temozolomide at 40 mg/kg (5 administrations per week for 5 consecutive weeks), or Narciclasine at 1 mg/kg either oral (once per week for 5 weeks) or i.v. (twice per week for 5 weeks). Drug administration is initiated respectively on days 5 and 7 post-tumor grafting for the Hs683 and GL19 models. The temozolomide dose and treatment schedule are selected based on previous optimized regimens. Narciclasine dose and treatment schedule are selected based on Narciclasine toxicity study in rats after oral administration and pharmacokinetic study that we have recently published. In toxicity study, Narciclasine (25, 10, or 1 mg/kg) is administered five times a week for 3 weeks and the no adverse effect level dose is defined to be 1 mg/kg/d p.o., with minimal acanthosis reactive changes and minor variations in some biochemistry parameters observed at this dose level considered to be nonadverse.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (284 KB)
SDS (418 KB)
- English - EN (418 KB)
- Français - FR (418 KB)
- Deutsch - DE (418 KB)
- Norwegian - NO (418 KB)
- Español - ES (418 KB)
- Swedish - SV (418 KB)
- Italian - IT (418 KB)
- Korean - KR (418 KB)
- Portuguese - PT (418 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Lefranc F, et al. Narciclasine, a plant growth modulator, activates Rho and stress fibers in glioblastoma cells. Mol Cancer Ther. 2009 Jul;8(7):1739-50. [Content Brief]

[2]. Wahyuni DS, et al. The use of bio-guided fractionation to explore the use of leftover biomass in Dutch flower bulb production as allelochemicals against weeds. Molecules. 2013 Apr 17;18(4):4510-25. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.2546 mL	16.2729 mL	32.5457 mL	81.3643 mL
	5 mM	0.6509 mL	3.2546 mL	6.5091 mL	16.2729 mL
	10 mM	0.3255 mL	1.6273 mL	3.2546 mL	8.1364 mL
	15 mM	0.2170 mL	1.0849 mL	2.1697 mL	5.4243 mL
	20 mM	0.1627 mL	0.8136 mL	1.6273 mL	4.0682 mL
	25 mM	0.1302 mL	0.6509 mL	1.3018 mL	3.2546 mL
	30 mM	0.1085 mL	0.5424 mL	1.0849 mL	2.7121 mL
	40 mM	0.0814 mL	0.4068 mL	0.8136 mL	2.0341 mL
	50 mM	0.0651 mL	0.3255 mL	0.6509 mL	1.6273 mL
	60 mM	0.0542 mL	0.2712 mL	0.5424 mL	1.3561 mL
	80 mM	0.0407 mL	0.2034 mL	0.4068 mL	1.0171 mL
	100 mM	0.0325 mL	0.1627 mL	0.3255 mL	0.8136 mL

Bioz

Keywords

Narciclasine

23 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

Narciclasine

Y-27632

Rhosin hydrochloride

Y-27632 dihydrochloride

Homoharringtonine

Anisomycin

Laduviglusib

Y-27632 dihydrochloride (Standard)

Paclitaxel

Rapamycin

Thiazovivin

Rhosin

XAV-939

Publications Citing Use of MedChemExpress (MCE) Narciclasine

Ver todos los productos específicos de isoformas ROCK

Actividad biológica

Chemical Information

Publications (23)

Solvente y solubilidad

Protocolo

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

Bioz

Narciclasine

Y-27632

Rhosin hydrochloride

Y-27632 dihydrochloride

Homoharringtonine

Anisomycin

Laduviglusib

Y-27632 dihydrochloride (Standard)

Paclitaxel

Rapamycin

Thiazovivin

Rhosin

XAV-939

Publications Citing Use of MedChemExpress (MCE) Narciclasine

Ver todos los productos específicos de isoformas ROCK

Actividad biológica

Chemical Information

Publications (23)

Solvente y solubilidad

Protocolo

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

Narciclasine Related Classifications

HY-16563 Related Classifications

Bioz